Cencora Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Adjusted Diluted EPS: $3.84, up 15% year-over-year.

Consolidated Revenue: $83.7 billion, a 6% increase driven by both U.S. and International Healthcare Solutions segments.

Gross Profit: $2.9 billion, an 18% increase, with a gross profit margin of 3.47%, up 37 basis points.

Operating Income: $1 billion, up 20% compared to the prior year quarter.

Full Year Revenue: $321.3 billion, up 9%.

Full Year Adjusted Free Cash Flow: $3 billion.

Dividend: Announced a 9% increase, marking the 21st consecutive annual dividend increase.

2Strategic Updates and Business Highlights

Cencora is focusing on three growth priorities: leading with market leaders, enhancing patient access to pharmaceuticals, and strengthening its position in specialty.

The company is making significant investments, including a $1 billion commitment to expand its distribution network by 2030.

Cencora has undertaken a strategic review, resulting in the classification of certain businesses (e.g., MWI Animal Health, Profarma) under "other" for better transparency and focus on growth-oriented investments.

The acquisition of Retina Consultants of America (RCA) has been highlighted as a key move to strengthen the specialty segment.

3Forward Guidance and Outlook

Fiscal 2026 Adjusted Diluted EPS Guidance: Expected to be between $17.45 and $17.75, representing growth of 9% to 11%.

Consolidated Revenue Growth: Projected between 5% to 7%.

Operating Income Growth: Expected to grow by 8% to 10%.

Long-term guidance for adjusted operating income growth raised to 6% to 9% and adjusted EPS growth to 9% to 13%.

4Challenges and Points of Concern

The company experienced a decline in operating income in the International Healthcare Solutions segment, down 2% year-over-year, primarily due to pressures in global consulting services.

A goodwill impairment of $724 million related to PharmaLex was noted, reflecting persistent demand challenges.

The loss of an oncology customer due to acquisition by a peer is expected to create headwinds in the first three quarters of fiscal 2026.

Increased net interest expense of $78 million due to debt raised for the RCA acquisition may impact profitability.

5Notable Q&A Insights

Management emphasized a disciplined approach to capital deployment, focusing on high-growth areas and strategic M&A, particularly in the specialty segment.

The integration of RCA and the pathway to full ownership of OneOncology were discussed as critical to enhancing the MSO platform and driving future growth.

Analysts raised concerns about the sustainability of high growth rates in the U.S. Healthcare Solutions segment, with management indicating confidence in maintaining strong performance despite headwinds.

The strategic review of "other" businesses is aimed at enhancing focus and potentially divesting non-core assets, which may lead to short-term dilution but is expected to benefit long-term growth. Overall, Cencora reported strong financial results and raised its long-term guidance, while also addressing challenges in specific segments and the strategic review of certain businesses.